Oncopeptides wins EU approval for Pepaxti as third-line multiple myeloma treatment

• Oncopeptides secured European Commission clearance to expand Pepaxti to third-line multiple myeloma treatment, removing the triple-class refractory requirement.
• Eligible adults must have received at least two prior therapies, with disease refractory to lenalidomide and their last treatment.
• Existing Phase 3 OCEAN results supporting the expansion showed earlier treatment enabled longer disease control and treatment duration.
• The expanded indication could double the eligible European patient population, increasing revenue potential through broader access and longer treatment.
• A German access submission is planned within approximately one month, allowing immediate third-line sales during benefit assessment and pricing negotiations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncopeptides AB published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.